Samumed to announce clinical data on potential treatment of androgenetic alopecia at WCHR

SAN DIEGO–November 18, 2015–Samumed, LLC, a leader in tissue regeneration, announced today that it will present clinical data on a small molecule (SM04554, an investigational new drug) for potential treatment of androgenetic alopecia (AGA), commonly known as male pattern baldness, at the 9th World Congress for Hair Research (WCHR) in Miami, Florida. The company is a Silver Sponsor of the meeting.

In preclinical in vivo studies, SM04554 has been shown to regenerate new hair follicles and increase hair count in multiple animal models. The company has finished a Phase I trial and is about to complete its Phase II trial with the same potential AGA treatment. At the WCHR, Samumed will present clinical results detailing safety, pK, and patient and investigator-reported efficacy data from a 28-day (14 day dosing, 14 days of follow-up), placebo-controlled, double-blind, randomized Phase I clinical trial of SM04554 in male AGA patients between the ages of 18 and 60 with Norwood-Hamilton Classification scores of 4, 5, 6, or 7.

"We are excited to present at the WCHR shortly after we presented results from our osteoarthritis program at the Annual Meeting of the American College of Rheumatology on November 9. Our technology platform focuses on small molecule drugs to repair/regenerate local tissue as diverse as hair and cartilage. Last week, we had shared both preclinical and clinical data from our osteoarthritis program, and this week we are excited to share clinical results from our alopecia program. We hope to present Phase II results from our AGA program very soon," said Yusuf Yazici, M.D., Chief Medical Officer of Samumed.


Saturday, November 21, 2015; 12:15pm

Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase I Trial
Session Title: Clinical Trials



Based in San Diego, CA, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.